Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Inclusion Criteria16

• \> 18 years of age
• Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:
• Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.
• Metastatic or Locally Advanced AND Inoperable
• Clear disease progression on Octreotide over less than 3 years (RECIST 1.1)
• Presence of disease within 24 weeks as identified by PET/CT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and/or PET/CT scans with FDG for transformation to high-grade NET
• Well differentiated on path - Ki67 \< 20%
• Octreotide positive on pathology (if not documented, acceptable if PET/CT imaging shows lesions with Ga-68 DOTATATE uptakeLabs:
• Cr. \<1.7
• Hgb \>8
• WBC \>2K
• Plt \>75K
• Bili \< 3x normal limit
• No Octreotide within 30 days of administration.
• Willing and able to comply with the protocol requirements
• Able to comprehend and sign the Informed Consent Form in English.